Overview A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer Status: Completed Trial end date: 2012-08-01 Target enrollment: Participant gender: Summary This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer Phase: Phase 2 Details Lead Sponsor: Eli Lilly and CompanyCollaborator: Genentech, Inc.Treatments: Albumin-Bound PaclitaxelBevacizumabGemcitabinePaclitaxel